Comparative effectiveness of cycling of tumor necrosis factor-α (TNF-α) inhibitors versus switching to non-TNF biologics in rheumatoid arthritis patients with inadequate response to TNF-α inhibitor using a Bayesian approach

详细信息    查看全文

• 作者：Hye-Lin Kim (1)
  Min-Young Lee (1)
  Sun-Young Park (1)
  Sun-Kyeong Park (1)
  Ji-Hye Byun (1)
  Sunhong Kwon (1)
  Eui-Kyung Lee (1)
  
• 关键词：Rheumatoid arthritis ; Inadequate response to TNF ; α inhibitors ; Comparative effectiveness ; American college of rheumatology (ACR) ; Health assessment questionnaire (HAQ)
• 刊名：Archives of Pharmacal Research
• 出版年：2014
• 出版时间：May 2014
• 年：2014
• 卷：37
• 期：5
• 页码：662-670
• 全文大小：
• 参考文献：1. CADTH therapeutic review. 2010. / Clinical and economic overview: biological response modifier agents for adults with rheumatoid arthritis. Canadian Agency for Drugs and Technologies in Health: Ottawa.
  2. Chatzidionysiou, K., and R.F. Van Vollenhoven. 2013. Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. / Scandinavian Journal of Rheumatology 42: 190-95. CrossRef
  3. Cohen, S.B., P. Emery, M.W. Greenwald, M. Dougados, R.A. Furie, M.C. Genovese, E.C. Keystone, J.E. Loveless, G.R. Burmester, M.W. Cravets, E.W. Hessey, T. Shaw, and M.C. Totoritis. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. / Arthritis and Rheumatism 54: 2793-806. CrossRef
  4. Devine, E.B., R. Alfonso-Cristancho, and S.D. Sullivan. 2011. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. / Pharmacotherapy 31: 39-1. CrossRef
  5. Dipiro, J.T., R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, and L.M. Posey. 2005. / Pharmacotherapy: a pathophysiologic approach. New York: McGraw-Hill.
  6. Emery, P., E. Keystone, H.P. Tony, A. Cantagrel, R. Van Vollenhoven, A. Sanchez, E. Alecock, J. Lee, and J. Kremer. 2008. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. / Annals of the Rheumatic Diseases 67: 1516-523. CrossRef
  7. Genovese, M.C., J.-C. Becker, M. Schiff, M. Luggen, Y. Sherrer, J. Kremer, C. Birbara, J. Box, K. Natarajan, I. Nuamah, T. Li, R. Aranda, D.T. Hagerty, and M. Dougados. 2005. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition. / New England Journal of Medicine 353: 1114-123. CrossRef
  8. Gomez-Reino, J.J., C. Rodriguez-Lozano, C. Campos-Fernandez, M. Montoro, M.A. Descalzo, and L. Carmona. 2012. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10?years: data from the Spanish registry BIOBADASER 2.0. / Annals of the Rheumatic Diseases 71: 382-85. CrossRef
  9. Guyot, P., P.C. Taylor, R. Christensen, L. Pericleous, P. Drost, I. Eijgelshoven, G. Bergman, and M. Lebmeier. 2012. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. / Journal of Rheumatology 39: 1198-206. CrossRef
  10. Horton, S., M.H. Buch, and P. Emery. 2010. Efficacy, tolerability and safety of biologic therapy in rheumatoid disease: patient considerations. / Drug Healthcare and Patient Safety 2: 101-19.
  11. Jang, E.J., D.H. Kim, J. Ahn, B.H. Jang, and S.M. Choi. 2013. / Methods for Bayesian meta-analysis. Seoul: National Evidence-based Healthcare Collaborating Agency.
  12. Jansen, J.P., B. Crawford, G. Bergman, and W. Stam. 2008. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. / Value Health 11: 956-64. CrossRef
  13. Krishnan, E., T. Sokka, A. Hakkinen, H. Hubert, and P. Hannonen. 2004. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. / Arthritis and Rheumatism 50: 953-60. CrossRef
  14. Launois, R., B. Avouac, F. Berenbaum, O. Blin, I. Bru, B. Fautrel, J.M. Joubert, J. Sibilia, and B. Combe. 2011. Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis. / Journal of Rheumatology 38: 835-45. CrossRef
  15. Lee, Y.H., J.H. Woo, Y.H. Rho, S.J. Choi, J.D. Ji, and G.G. Song. 2008. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. / Rheumatology International 28: 553-59. CrossRef
  16. Lu, G., and A.E. Ades. 2004. Combination of direct and indirect evidence in mixed treatment comparisons. / Statistics in Medicine 23: 3105-124. CrossRef
  17. Miranda, L.C., H. Santos, J. Ferreira, P. Coelho, C. Silva, and J. Saraiva-Ribeiro. 2012. Finding rheumatoid arthritis impact on life (FRAIL Study): economic burden. / Acta Reumatologica Portuguesa 37: 134-42.
  18. Moran, J.L., P.L. Graham, S. Rockliff, and A.D. Bersten. 2010. Updating the evidence for the role of corticosteroids in severe sepsis and septic shock: a Bayesian meta-analytic perspective. / Critical Care 14: R134. CrossRef
  19. O’dell, J.R. 2004. Therapeutic strategies for rheumatoid arthritis. / New England Journal of Medicine 350: 2591-602. CrossRef
  20. Odeg?rd, S., A. Finset, T.K. Kvien, P. Mowinckel, and T. Uhlig. 2005. Work disability in rheumatoid arthritis is predicted by physical and psychological health status: a 7-year study from the Oslo RA register. / Scandinavian Journal of Rheumatology 34: 441-47. CrossRef
  21. Orme, M.E., K.S. Macgilchrist, S. Mitchell, D. Spurden, and A. Bird. 2012. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70. / Biologics 6: 429-64.
  22. Ruderman, E.M. 2012. Overview of safety of non-biologic and biologic DMARDs. / Rheumatology 51(Suppl 6): vi37–vi43. CrossRef
  23. Salliot, C., A. Finckh, W. Katchamart, Y. Lu, Y. Sun, C. Bombardier, and E. Keystone. 2011. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. / Annals of the Rheumatic Diseases 70: 266-71. CrossRef
  24. Schmitz, S., R. Adams, C.D. Walsh, M. Barry, and O. Fitzgerald. 2012. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. / Annals of the Rheumatic Diseases 71: 225-30. CrossRef
  25. Singh, J.A., D.E. Furst, A. Bharat, J.R. Curtis, A.F. Kavanaugh, J.M. Kremer, L.W. Moreland, J. O’dell, K.L. Winthrop, T. Beukelman, S.L. Bridges Jr, W.W. Chatham, H.E. Paulus, M. Suarez-Almazor, C. Bombardier, M. Dougados, D. Khanna, C.M. King, A.L. Leong, E.L. Matteson, J.T. Schousboe, E. Moynihan, K.S. Kolba, A. Jain, E.R. Volkmann, H. Agrawal, S. Bae, A.S. Mudano, N.M. Patkar, and K.G. Saag. 2012. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. / Arthritis Care & Research 64: 625-39. CrossRef
  26. Smith, H.S., A.R. Smith, and P. Seidner. 2011. Painful rheumatoid arthritis. / Pain Physician 14: E427–E458.
  27. Smolen, J.S., J. Kay, M.K. Doyle, R. Landewe, E.L. Matteson, J. Wollenhaupt, N. Gaylis, F.T. Murphy, J.S. Neal, Y. Zhou, S. Visvanathan, E.C. Hsia, and M.U. Rahman. 2009. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. / Lancet 374: 210-21. CrossRef
  28. Smolen, J.S., R. Landewe, F.C. Breedveld, M. Buch, G. Burmester, M. Dougados, P. Emery, C. Gaujoux-Viala, L. Gossec, J. Nam, S. Ramiro, K. Winthrop, M. De Wit, D. Aletaha, N. Betteridge, J.W. Bijlsma, M. Boers, F. Buttgereit, B. Combe, M. Cutolo, N. Damjanov, J.M. Hazes, M. Kouloumas, T.K. Kvien, X. Mariette, K. Pavelka, P.L. Van Riel, A. Rubbert-Roth, M. Scholte-Voshaar, D.L. Scott, T. Sokka-Isler, J.B. Wong, and D. Van Der Heijde. 2013. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. / Annals of the Rheumatic Diseases. doi:10.1136/annrheumdis-2013-204573 .
  29. Smolen, J.S., R. Landewe, F.C. Breedveld, M. Dougados, P. Emery, C. Gaujoux-Viala, S. Gorter, R. Knevel, J. Nam, M. Schoels, D. Aletaha, M. Buch, L. Gossec, T. Huizinga, J.W. Bijlsma, G. Burmester, B. Combe, M. Cutolo, C. Gabay, J. Gomez-Reino, M. Kouloumas, T.K. Kvien, E. Martin-Mola, I. Mcinnes, K. Pavelka, P. Van Riel, M. Scholte, D.L. Scott, T. Sokka, G. Valesini, R. Van Vollenhoven, K.L. Winthrop, J. Wong, A. Zink, and D. Van Der Heijde. 2010. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. / Annals of the Rheumatic Diseases 69: 964-75. CrossRef
  30. Soliman, M.M., K.L. Hyrich, M. Lunt, K.D. Watson, D.P.M. Symmons, and D.M. Ashcroft. 2012. On Behalf of the British Society for Rheumatology Biologics, R. Rituximab or a second anti-tumor necrosis factor therapy for rheumatoid arthritis patients who have failed their first anti-tumor necrosis factor therapy? Comparative analysis from the British Society for Rheumatology Biologics Register. / Arthritis Care & Research 64: 1108-115.
  31. Strand, V., G.R. Burmester, S. Ogale, J. Devenport, A. John, and P. Emery. 2012a. Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. / Rheumatology 51: 1860-869. CrossRef
  32. Strand, V., V. Sharp, A.S. Koenig, G. Park, Y. Shi, B. Wang, D.J. Zack, and D. Fiorentino. 2012b. Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. / Annals of the Rheumatic Diseases 71: 1143-150. CrossRef
  33. Strand, V., and J.A. Singh. 2008. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. / American Journal of Managed Care 14: 234-54.
  34. Westhovens, R., J.C. Cole, T. Li, M. Martin, R. Maclean, P. Lin, B. Blaisdell, G.V. Wallenstein, R. Aranda, and Y. Sherrer. 2006. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. / Rheumatology 45: 1238-246. CrossRef
  
• 作者单位：Hye-Lin Kim (1)
  Min-Young Lee (1)
  Sun-Young Park (1)
  Sun-Kyeong Park (1)
  Ji-Hye Byun (1)
  Sunhong Kwon (1)
  Eui-Kyung Lee (1)
  
  1. School of Pharmacy, Sungkyunkwan University, 300 Cheonchoen-dong, Jangan-gu, Suwon, Gyeonggi-do, 440-746, South Korea
  
• ISSN：1976-3786

文摘

Alternative tumor necrosis factor-α (TNF-α) inhibitors and non-TNF biologics are available as treatment options for rheumatoid arthritis patients who exhibit inadequate response to TNF-α inhibitor (TNF-IR patients). These agents have considerable efficacy compared with placebo, but head-to-head comparisons among these agents have not been performed. The objective of this study was to use Bayesian approach to compare the effectiveness of cycling TNF-α inhibitors versus switching to non-TNF biologics in TNF-IR patients. A systematic review was conducted using MEDLINE and Cochrane library. Key endpoints were the American College of Rheumatology (ACR) responses of 20/50/70 and the health assessment questionnaire (HAQ) score change at six months. Bayesian outcomes were calculated as the probability that OR is greater than one and HAQ score change difference is less than zero. Compared with TNF-α inhibitors, non-TNF biologics were associated with higher ACR response rates; in ACR20, the OR was 1.639 for abatacept [P(OR?>?1)?=?90.7?%], 1.871 for rituximab [P(OR?>?1)?=?96.2?%] and 3.52 for tocilizumab [P(OR?>?1)?=?99.9?%]. Similar trends were shown in the HAQ change comparison; the median differences (MD) were ?.259 for abatacept [P(MD?<?0)?=?100?%], ?.160 for rituximab [P(MD?<?0)?=?98.2?%], and ?.200 for tocilizumab [P(MD?<?0)?=?99.3?%]. In conclusion, switching to non-TNF biologics was more effective than cycling TNF-α inhibitor in TNF-IR patients.